Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System AtrophyMASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy ...
Fast Track designation indicates LBS-007’s potential in filling the unmet medical need of acute leukemia; LBS-007 is the Company’s investigational medicinal product for the tr ...